PRODUCT LAUNCH PRESS RELEASE
Morphormics launches its first product, MxStruct® for male pelvis auto-segmentation

FDA PRESS RELEASE
FDA clears first Morphormics autosegmentation product

ACCURAY PRESS RELEASE
Accuray Licenses Technology from Morphormics for Prostate Cancer Treatment Planning

UNIVERSITY OF NORTH CAROLINA PRESS RELEASE
UNC spin-off company receives $2 million grant to market cancer treatment technology

Morphormics Launches 1ST Product at ASTRO

Chicago, November 1, 2009 - Morphormics, Incorporated, a leader in the development of computer-based technology for medical image analysis, announced today the commercial launch of its first product, MxStruct® for male pelvis auto-segmentation. Read More

FDA Clears First Morphormics Autosegmentation Product

Chapel Hill, May 19, 2009 - Morphormics, Incorporated, an international leader in the development of computer-based technology for medical image analysis, announced today that the Food and Drug Administration has cleared its first product in the U.S. market as a component of Accuray's MultiPlan® Treatment Planning System. Morphormics' MxStruct software segments anatomical structures for radiotherapy and
radiosurgery treatment planning. Read More

Accuray Licenses Technology from Morphormics for Prostate Cancer Treatment Planning
Investment Confirms Company's Commitment to Improving Ability to Treat Prostate

BOSTON, September 22, 2008 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company is partnering with Morphormics Incorporated, a start-up company out of the University of North Carolina at Chapel Hill, in the development and licensing of autocontouring technology. The technology automatically identifies and draws the boundaries of the prostate and surrounding critical structures, enabling the treatment planning software to focus radiation dose on the prostate and minimize delivering dose to the surrounding critical structures. This partnership reflects Accuray's focus on advanced technologies to improve the treatment of prostate cancer. Read More

UNC spin-off company receives $2 million grant to market cancer treatment technology

A University of North Carolina at Chapel Hill spin-off company has been awarded a $2 million grant to commercialize a new technology to improve radiation treatment of prostate cancer.

The grant from the National Cancer Institute, as part of its Small Business Innovation Research program, will enable Morphormics Inc. to market its proprietary technology for rapidly constructing anatomical "roadmaps" of individual patients. Read More